All In Biotech

Drug Trial Radar · NCT06126653

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder

A Blinded, Cross-Over Study to Evaluate the Safety and Efficacy of ARD-501 in Patients With Autism Spectrum Disorder

Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5

Actual

Start

Aug 1, 2024

Primary completion

Jan 13, 2025

Study completion Jan 13, 2025

Sponsor

Lead sponsor
Aardvark Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Center for Psychiatry And Behavioral Medicine Inc.
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 17 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a blinded, placebo controlled, cross-over trial evaluating the safety of two dose-levels of ARD-501 in subjects with ASD.

Conditions

  • Autism Spectrum Disorder

Interventions

  • Low Dose ARD-501Drug

    Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.2 mg/kg dosing.

  • High Dose ARD-501Drug

    Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.

  • PlaceboDrug

    Titratable, liquid formulation, taken orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the incidence of Treatment-Emergent Adverse Events (TEAE)Time frame: Baseline to Week 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Psychiatry and Behavioral Medicine Inc

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.